Seed VC · USA

JP Morgan Private Capital

Active

What they invest in

The fund invests in private biotechnology companies across stage, modality, therapeutic area, and geography, with a mission to identify and support innovative companies that can shape the future of patient treatment while utilizing collective experience to guide portfolio companies toward successful outcomes.

Who they back

DeepTechAIHealthtechBiotechLife sciences & biotech VC & Growth fundPre-seedSeedSeries ASeries B+

Business models

deeptech_ip, biotech_therapeutics

Customer segments

Researchers

Geography

US

The people who write checks

2 partners on file at JP Morgan Private Capital, with the firm's email pattern for cold outreach. Score your deck (free, 30 seconds) to unlock direct contact for this firm and 47,000+ others.

We never publish partner emails directly — score your deck to unlock contacts for the firms ranked as best-fit.

Why this firm matters for fundraising founders

JP Morgan Private Capital writes first institutional checks where the founder + early product matter more than traction. The seed market is the most dispersed segment of venture; matching to thesis (sector, stage, geography) is where most cold outreach succeeds or fails. VCboom tracks JP Morgan Private Capital alongside 47,000+ other active investors, ranked weekly by recent-deal momentum, sector concentration, and partner activity.

At a glance

Based in
United States
Last known deal
Jun 2024
Website
am.jpmorgan.com/us/en/asset-management/adv/about-us/media/press-releases/jp-morgan-life-sciences-private-capital-closes-inaugural-biotechnology-venture-fund

Other firms investing in DeepTech

See all investors →

Is JP Morgan Private Capital the right fit for your deck?

Drop your pitch. AI scores it on the 8 dimensions VCs read for and ranks the 47,000+ active investors in the database by fit. JP Morgan Private Capital is one of them — and we'll tell you exactly where they sit in your top 100.